Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

Background: Cognitive impairment in MS impacts negatively on many patients at all disease stages and in all subtypes. Full clinical cognitive assessment is expensive, requiring expert staff and special equipment. Test versions and normative data are not available for all languages and cultures. Objective: To recommend a brief cognitive assessment for multiple sclerosis (MS) that is optimized for small centers, with one or few staff members, who may not have neuropsychological training and constructed to maximize international use. Methods: An expert committee of twelve members representing the main cultural groups that have so far contributed considerable data about MS cognitive dysfunction was convened. Following exhaustive literature review, peer-reviewed articles were selected to cover a broad spectrum of cultures and scales that targeted cognitive domains vulnerable to MS. Each was rated by two committee members and candidates scales were rated on psychometric qualities (reliability, validity, and sensitivity), international application, ease of administration, feasibility in the specified context, and acceptability to patients. Results: The committee recommended the Symbol Digit Modalities Test, if only 5 minutes was available, with the addition of the California Verbal Learning Test – Second Edition and the Brief Visuospatial Memory Test – Revised learning trials if a further 10 minutes could be allocated for testing. Conclusions: A brief cognitive assessment for MS has been recommended. A validation protocol has been prepared for language groups and validation studies have commenced.

[1]  C H Polman,et al.  The Brief Repeatable Battery of Neuropsychological Tests: normative values allow application in multiple sclerosis clinical practice , 2001, Multiple sclerosis.

[2]  M. Bonnet,et al.  How to detect cognitive dysfunction at early stages of multiple sclerosis? , 2006, Multiple sclerosis.

[3]  M. Deloire,et al.  An unusual cause of isolated vomiting , 2011, Neurology.

[4]  J. Grafman,et al.  Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. , 2000, Annals of neurology.

[5]  J. Baños,et al.  California Verbal Learning Test-Second Edition , 2002 .

[6]  J. Grafman,et al.  Neuropsychological effects of interferon β‐1a in relapsing multiple sclerosis , 2000 .

[7]  S. Sangiorgi,et al.  Relationship between intrathecal baclofen and the central nervous system. , 2007, Acta neurochirurgica. Supplement.

[8]  Resolution of left hemisphere cognitive dysfunction in multiple sclerosis with magnetic resonance correlates: a case report. , 1996, Cognitive neuropsychiatry.

[9]  F. Munschauer,et al.  Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test , 2007, Multiple sclerosis.

[10]  Amanda R. Rabinowitz,et al.  A longitudinal analysis of cognitive dysfunction, coping, and depression in multiple sclerosis. , 2009, Neuropsychology.

[11]  Emily Snook,et al.  Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis , 2008, Multiple Sclerosis.

[12]  D. Delis,et al.  California Verbal Learning Test--Second Edition , 2016 .

[13]  L. Messinis,et al.  MULTIPLE SCLEROSIS AND CANNABIS: A COGNITIVE AND PSYCHIATRIC STUDY , 2009, Neurology.

[14]  L. von Koch,et al.  Cognitive and motor function in people with multiple sclerosis in Stockholm County , 2006, Multiple sclerosis.

[15]  P. Arnett,et al.  Dysarthria predicts poorer performance on cognitive tasks requiring a speeded oral response in an MS population , 2007, Journal of clinical and experimental neuropsychology.

[16]  H. Hartung,et al.  The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): First Consensus Steps Towards a Brief Universal Cognitive Assessment for MS , 2011 .

[17]  S. Rombouts,et al.  The contribution of MRI in assessing cognitive impairment in multiple sclerosis , 2010, Neurology.

[18]  Eric Achten,et al.  Transverse diffusivity of cerebral parenchyma predicts visual tracking performance in relapsing–remitting multiple sclerosis , 2009, Brain and Cognition.

[19]  M. Amato,et al.  Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study , 2010, Multiple sclerosis.

[20]  R. Bakshi,et al.  Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[21]  P. Shekelle,et al.  Title Quality indicators for multiple sclerosis Permalink , 2010 .

[22]  M. Brodie,et al.  Pharmacotherapy of Epilepsy , 2011, CNS drugs.

[23]  V. Dousset,et al.  Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study , 2008, Multiple sclerosis.

[24]  R. Brunner,et al.  Effect of High‐Dose Cortisol on Memory Functions , 2006, Annals of the New York Academy of Sciences.

[25]  D. Goodin,et al.  Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. , 2009, Clinical therapeutics.

[26]  A. Thompson,et al.  Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. , 1999, Brain : a journal of neurology.

[27]  Eben S. Schwartz,et al.  Validity of the California Verbal Learning Test–II in Multiple Sclerosis , 2010, The Clinical neuropsychologist.

[28]  Faan Nancy L. Sicotte MD.  Neuroimaging in Multiple Sclerosis: Neurotherapeutic Implications , 2010, Neurotherapeutics.

[29]  I. Hindmarch.  Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder , 2009, International journal of clinical practice.

[30]  R. Benedict,et al.  Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline , 2010, The Clinical neuropsychologist.

[31]  D. Mohr,et al.  Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. , 2010, Neuropsychology.

[32]  Ralph H B Benedict,et al.  Minimal Neuropsychological Assessment of MS Patients: A Consensus Approach , 2002, The Clinical neuropsychologist.

[33]  R. Aupperle,et al.  Three screening batteries to detect cognitive impairment in multiple sclerosis , 2002, Multiple sclerosis.

[34]  C R G Guttmann,et al.  Thalamic atrophy and cognition in multiple sclerosis , 2007, Neurology.

[35]  R. Marrie,et al.  Validity of performance scales for disability assessment in multiple sclerosis , 2007, Multiple sclerosis.

[36]  Jared M. Bruce,et al.  Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS , 2007, Journal of the International Neuropsychological Society.

[37]  R Bakshi,et al.  Identification and Clinical Impact of Multiple Sclerosis Cortical Lesions as Assessed by Routine 3T MR Imaging , 2011, American Journal of Neuroradiology.

[38]  L. Krupp,et al.  Multiple sclerosis-associated fatigue , 2010, Expert review of neurotherapeutics.

[39]  L. Rapport,et al.  Awareness of deficit in multiple sclerosis , 2008, Journal of clinical and experimental neuropsychology.

[40]  R. Benedict,et al.  Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test , 2010, Multiple sclerosis.

[41]  R. Benedict,et al.  Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) , 2006, Journal of the International Neuropsychological Society.

[42]  R. Benedict,et al.  Reliable screening for neuropsychological impairment in multiple sclerosis , 2004, Multiple sclerosis.

[43]  G. Siracusa,et al.  Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis , 2008, Neurology.

[44]  D. Langdon,et al.  Cognitive Impairment in Multiple Sclerosis - Recent Advances and Future Prospects , 2010 .

[45]  Bernd Tomandl,et al.  The association between California Verbal Learning Test performance and fibre impairment in multiple sclerosis: evidence from diffusion tensor imaging , 2010, Multiple sclerosis.

[46]  B. Oken,et al.  Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity. , 2006, Journal of rehabilitation research and development.

[47]  A. Thompson,et al.  A longitudinal study of cognition in primary progressive multiple sclerosis. , 2005, Brain : a journal of neurology.

[48]  Nathan Griffith,et al.  Treatment of Cognitive Impairment in Multiple Sclerosis , 2006, Behavioural neurology.

[49]  D. Ramasamy,et al.  Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[50]  G. Edan,et al.  Assessment of cognitive dysfunction in multiple sclerosis , 2006, Journal of the Neurological Sciences.

[51]  A. Iudice,et al.  Reliability, practice effects, and change indices for Rao’s brief repeatable battery , 2010, Multiple sclerosis.

[52]  B. Weinstock-Guttman,et al.  Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire , 2008, Multiple sclerosis.

[53]  T. Olsson,et al.  A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis , 2011, Multiple sclerosis.

[54]  Stephen M. Rao,et al.  Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS , 2009, Multiple sclerosis.

[55]  Rohit Bakshi,et al.  Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[56]  I. Evangelou,et al.  Quality and Quantity of Diffuse and Focal White Matter Disease and Cognitive Disability of Patients with Multiple Sclerosis , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[57]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[58]  S. Sorbi,et al.  The Rao’s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population , 2006, Multiple sclerosis.